Mirati Therapeutics
Bookmark
ShareMirati Therapeutics is a company. It is in San Diego, the United States and it has a male CEO called David D. Meek. It was founded in 2013 and is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: San Diego
- state: CA
- country: United States
- employees: 413 people
- revenues: 72.8M $
- sector: Health Care
- industry: Biotechnology
- foundation year: 2013
- CEO: David D. Meek
- CEO gender: male
- ESG score: Try Pro to see estimate
- environmental score (ESG): Try Pro to see estimate
- social score (ESG): Try Pro to see estimate
- governance score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about Mirati Therapeutics:
Dataset of stocks from Mirati Therapeutics:
Mirati Therapeutics is one of the companies in Biotechnology, companies in Health Care, companies in San Diego, companies in the United States and 3,456,835 companies in our database.
Talking Points
- Global Biopharmaceutical CompanyBristol Myers Squibb
- Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
- Our mission is to discover, design & deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. https://t.co/nXoCkyY6VT
- 201-500 employees Headquarters San Diego, California Type Public Company Founded 2013 Locations Primary 3545 Cray Ct San Diego, California 92121, US Get directions Employees at Mirati Therapeutics...
- Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
